Search Results - "Lowy, I."

Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors by Lewis, K D, Peris, K, Sekulic, A, Stratigos, A J, Dunn, L, Eroglu, Z, Chang, A L S, Migden, M R, Yoo, S-Y, Mohan, K, Coates, E, Okoye, E, Bowler, T, Baurain, J-F, Bechter, O, Hauschild, A, Butler, M O, Hernandez-Aya, L, Licitra, L, Neves, R I, Ruiz, E S, Seebach, F, Lowy, I, Goncalves, P, Fury, M G

“…Metastatic basal cell carcinoma (mBCC) is a rare condition with no effective second-line treatment options. Cemiplimab is an immune checkpoint inhibitor that…”
Get more information

GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer by Tewari, K.S., Vergote, I., Oaknin, A., Alvarez, E., Gaillard, S., Lheureux, S., Rischin, D., Santin, A.D., Feng, M., Mathias, M., Fury, M., Lowy, I., Monk, B.J.

Get full text

Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study by Pishvaian, M.J., Weiss, G.J., Falchook, G.S., Yee, N., Gil-Martin, M., Shahda, S., Moreno, V., Brana, I., Crittenden, M., Formenti, S., Al-Rajabi, R., Papadopoulos, K.P., Stankevich, E., Feng, M., Li, J., Mathias, M., Kroog, G., Lowy, I., Fury, M.G.

Get full text

Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts by Rischin, D., Gil-Martin, M., González-Martín, A., Brana, I., Hou, J.Y., Cho, D., Falchook, G.S., Formenti, S., Jabbour, S., Moore, K., Naing, A., Papadopoulos, K.P., Baranda, J., Weise, A., Fury, M.G., Feng, M., Li, J., Lowy, I., Mathias, M.

Get full text

Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data by Owonikoko, T.K., Papadopoulos, K.P., Gil-Martin, M., Moreno, V., Salama, A.K., Calvo, E., Safran, H., González-Martín, A., Aljumaily, R., Mahadevan, D., Niu, J., Kal Mohan, K., Li, J., Stankevich, E., Mathias, M., Lowy, I., Fury, M.G., Babiker, H.M.

Get full text

Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2) by Moreno, V., Gil-Martin, M., Johnson, M., Aljumaily, R., Lopez Criado, P., Northfelt, D.W., Crittenden, M., Jabbour, S., Rosen, L., Garrido Lopez, P., Hervás Morón, A., Rietschel, P., Mohan, K.K., Li, J., Stankevich, E., Rowlands, T., Feng, M., Lowy, I., Fury, M.G.

Get full text

Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) by Babiker, H.M., Brana, I., Mahadevan, D., Owonikoko, T.K., Calvo, E., Rischin, D., Moreno, V., Papadopoulos, K.P., Crittenden, M., Formenti, S., Giralt, J., Garrido Lopez, P., Hervás Morón, A., Mohan, K.K., Fury, M.G., Lowy, I., Stankevich, E., Feng, M., Li, J., Mathias, M.

Get full text

CLINICAL ACTIVITY OF REGN1979, AN ANTI‐CD20 X ANTI‐CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) by Topp, M.S., Arnason, J., Advani, R., Brown, J.R., Allan, J., Ansell, S., O'Brien, S., Chavez, J., Duell, J., Rosenwald, A., Charnas, R., Ambati, S.R., Adriaens, L., Ufkin, M., Zhu, M., Li, J., Gasparini, P., Jankovic, V., Fiaschi, N., Zhang, W., Hamon, S., Thurston, G., Murphy, A.J., Yancopoulos, G.D., Lowy, I., Sternberg, D., Bannerji, R.

Get full text

Hormone replacement therapy, cancer, controversies, and women’s health: historical, epidemiological, biological, clinical, and advocacy perspectives by Krieger, Nancy, Löwy, Ilana, Aronowitz, Robert, Bigby, Judyann, Dickersin, Kay, Garner, Elizabeth, Gaudillière, Jean-Paul, Hinestrosa, Carolina, Hubbard, Ruth, Johnson, Paula A, Missmer, Stacey A, Norsigian, Judy, Pearson, Cynthia, Rosenberg, Charles E, Rosenberg, Lynn, Rosenkrantz, Barbara G, Seaman, Barbara, Sonnenschein, Carlos, Soto, Ana M, Thornton, Joe, Weisz, George

“…Routine acceptance of use of hormone replacement therapy (HRT) was shattered in 2002 when results of the largest HRT randomised clinical trial, the women’s…”
Get full text

Human Immunodeficiency Virus Type 1 Mutants Resistant to Nonnucleoside Inhibitors of Reverse Transcriptase Arise in Tissue Culture by Richman, D, Shih, C K, Lowy, I, Rose, J, Prodanovich, P, Goff, S, Griffin, J

“…We have recently described a nonnucleoside compound that specifically inhibits the reverse transcriptase of human immunodeficiency virus type 1 (HIV-1), the…”
Get full text

Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity by Reicin, A S, Paik, S, Berkowitz, R D, Luban, J, Lowy, I, Goff, S P

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma by Migden, Michael R, Rischin, Danny, Schmults, Chrysalyne D, Guminski, Alexander, Hauschild, Axel, Lewis, Karl D, Chung, Christine H, Hernandez-Aya, Leonel, Lim, Annette M, Chang, Anne Lynn S, Rabinowits, Guilherme, Thai, Alesha A, Dunn, Lara A, Hughes, Brett G.M, Khushalani, Nikhil I, Modi, Badri, Schadendorf, Dirk, Gao, Bo, Seebach, Frank, Li, Siyu, Li, Jingjin, Mathias, Melissa, Booth, Jocelyn, Mohan, Kosalai, Stankevich, Elizabeth, Babiker, Hani M, Brana, Irene, Gil-Martin, Marta, Homsi, Jade, Johnson, Melissa L, Moreno, Victor, Niu, Jiaxin, Owonikoko, Taofeek K, Papadopoulos, Kyriakos P, Yancopoulos, George D, Lowy, Israel, Fury, Matthew G

“…Among patients with advanced cutaneous squamous-cell carcinoma, the PD-1 inhibitor cemiplimab induced a response in approximately half the patients and was…”
Get full text

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma by Gross, Neil D., Miller, David M., Khushalani, Nikhil I., Divi, Vasu, Ruiz, Emily S., Lipson, Evan J., Meier, Friedegund, Su, Yungpo B., Swiecicki, Paul L., Atlas, Jennifer, Geiger, Jessica L., Hauschild, Axel, Choe, Jennifer H., Hughes, Brett G.M., Schadendorf, Dirk, Patel, Vishal A., Homsi, Jade, Taube, Janis M., Lim, Annette M., Ferrarotto, Renata, Kaufman, Howard L., Seebach, Frank, Lowy, Israel, Yoo, Suk-Young, Mathias, Melissa, Fenech, Keilah, Han, Hyunsil, Fury, Matthew G., Rischin, Danny

“…A phase 2, multicenter study showed that four doses of neoadjuvant cemiplimab (anti–PD-1 antibody) led to a pathological complete response in 51% of patients…”
Get full text

790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel) by Hamid, O., Weise, A., Kim, T.M., Mckean, M.A., Lakhani, N.J., Kaczmar, J., Papadopoulos, K.P., Chen, S., Mani, J., Jankovic, V., Kroog, G., Sims, T., Lowy, I., Gullo, G.

Get full text

1372TiP - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC) by Rischin, D., Fury, M.G., Lowy, I., Stankevich, E., Li, S., Han, H., Porceddu, S.V.

“…CSCC is the second most common skin cancer. While the surgical cure rate for CSCC is>95%, a proportion of pts are considered to have high-risk for recurrence…”
Get full text

A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC) by Rischin, D., Fury, M.G., Lowy, I., Stankevich, E., Li, S., Han, H., Porceddu, S.V.

Get full text

1372TiPA phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC) by Rischin, D, Fury, M G, Lowy, I, Stankevich, E, Li, S, Han, H, Porceddu, S V

“…Abstract Background CSCC is the second most common skin cancer. While the surgical cure rate for CSCC is > 95%, a proportion of pts are considered to have…”
Get full text

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma by ROYAL, Richard E, LEVY, Catherine, ROSENBERG, Steven A, TURNER, Keli, MATHUR, Aarti, HUGHES, Marybeth, KAMMULA, Udai S, SHERRY, Richard M, TOPALIAN, Suzanne L, YANG, James C, LOWY, Israel

“…New, effective therapies are needed for pancreatic ductal adenocarcinoma. Ipilimumab can mediate an immunologic tumor regression in other histologies. This…”
Get full text

C-POST Protocol Update: A Phase 3, Randomized, Double-Blind Study of Adjuvant Cemiplimab vs. Placebo Post Surgery and Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma by Rischin, D., Brungs, D., Day, F., Christie, H., Patel, V.A., Adams, G., Jackson, J.E., Schurmann, M.D.L.V., Kirtbaya, D., Shin, T.M., Hart, C.D., Stankevich, E., Li, S., Lowy, I., Han, H., Fury, M.G., Porceddu, S.

Get full text

327P Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial by Ho, G.F., Ozguroglu, M., Kilickap, S., Sezer, A., Gumus, M., Bondarenko, I., Gogishvili, M., Nechaeva, M., Schenker, M., Cicin, I., Kulyaba, Y., Dvorkin, M., Zyuhal, K., Scheusan, R.I., Li, S., Pouliot, J-F., Seebach, F., Lowy, I., Gullo, G., Rietschel, P.

Get full text